Kura Oncology, Inc. · NASDAQ:KURA
Kura Oncology — Investor Presentation (February 2016)
23 slides from Kura Oncology's investor presentation, Feb 10, 2016
Slide 1: Kura Oncology Investor Presentation, February 2016
Troy Wilson, Ph.D., J.D., President and CEO February 2016 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, pre-clinical and clinical development activities, plans and projected timelines for tipifarnib, and our other programs, plans regardin
Slide 3: Corporate Overview
Corporate Overview Develop a diverse pipeline of targeted therapeutics for solid tumors and blood cancers Utilize precision medicine approaches to identify patients most likely to benefit from treatments Fast-to-market strategy; broaden indication set after clinical POC Development Strategy Experien
Slide 4: Diverse Development Pipeline
Diverse Development Pipeline PROGRAM LEAD OPTIMIZATION PRECLINICAL PHASE 1 PHASE 2 Tipifarnib Farnesyl Transferase Inhibitor KO-947 ERK inhibitor Menin- MLL inhibitor HRAS Mutant Solid Tumors Peripheral T Cell Lymphoma MAPK Pathway Tumors Acute Leukemias Lower Risk Myelodysplastic Syndromes MULTIPLE
Slide 5: Tipifarnib – Lead Product Candidate
Tipifarnib – LEAD Product CANDIDATE Licensed worldwide rights in oncology from Janssen Broad development program, which preceded precision medicine approach Studied in > 5,000 patients Generally well-tolerated ORRs range from < 10-40% in unselected populations Evidence of durable clinical benefit in
Slide 6: Tipifarnib MOA supports development in HRAS mutant solid tumors
Tipifarnib MOA supports development In HRAS mutant solid Tumors F Farnesyl transferase F Geranylgeranyl transferase F GG Cytosolic, inactive Membrane-bound, active Alternative prenylation of KRAS and NRAS F GG Farnesyl group Geranylgeranyl group K/N/HRAS Tipifarnib TIPIFARNIB INHIBITS HRAS SIGNALING
Slide 7: Strong Scientific Rationale to Target HRAS Mutant Solid Tumors
Strong Scientific Rationale to target HRAS mutant solid Tumors TISSUE HRAS MUTATION FREQUENCY Salivary gland 15% Urinary tract 11% Cervix 9% Upper aerodigestive tract 9% Prostate 6% Skin 6% Stomach 4% Testis 4% Thyroid 3% Collective US Incidence ~ 8,000 HRAS has potential to be driver oncogene (Cost
Slide 8: Phase 2 Activity of Tipifarnib Observed in Peripheral T-Cell Lymphomas
Phase 2 Activity of Tipifarnib Has Been observed in Peripheral T-Cell Lymphomas Tipifarnib was previously studied in a 93 patient Phase 2 trial of various relapsed/refractory lymphomas1 High activity observed in third cohort – heavily pretreated patients with T-Cell and Hodgkin’s Lymphoma ORR: 31% 8
Slide 9: Tipifarnib activity compares favorably to current standards of care
N Prior Therapy median CR (%) ORR (%) Median PFS/TTP (mos) Median OS (mos) 120 2 11 26 1.6 7.9 130 2 15 25 4.0 11.3 109 3 8 27 3.5 14.5 Tipifarnib (T-cell / Hodgkin’s Lymphoma) 36 ≥ 4 172 31 3.2 19.7 TIPIFARNIB activity compares favorably to current standards of care 1 Table lists data from separate
Slide 10: Strong Rationale for Investigating Tipifarnib in Myelodysplastic Syndromes
Strong Rationale for investigating tipifarnib in myeloDysplastic Syndromes MDS interferes with normal stem cell differentiation, resulting in cytopenias and carries a risk for transformation into AML Represents a significant unmet medical need U.S. incidence of 13,000; prevalence of > 60,000 cases 7
Slide 11: Opportunity with Myelodysplastic Syndromes: Prior Clinical Experience
Opportunity with myelodysplastic syndromes: Prior clinical experience Tipifarnib has shown promising activity in intermediate/high-risk MDS in a previous Phase 2 study (sponsored by Johnson & Johnson) *Defined by International Prognostic Scoring System (IPSS) 3 Study INT-28: Intermediate/High Risk M
Slide 12: Expression of KIR2DS2 correlates with tipifarnib clinical benefit in AML
Expression of kir2DS2 correlates with tipifarnib clinical Benefit in AML 0 200 400 600 800 1000 0 20 40 60 80 100 Time (days) Survival probability (%) Time (days) Tipifarnib Treated Patients (n=34) NCI CTEP-20 Study P = 0.0074 High KIR2DS2 Median OS: 564 days Low KIR2DS2 Median OS: 153 days 0 200 40
Slide 13: Investigating multiple clinical hypotheses
Investigating multiple clinical hypotheses HRAS Mutant Tumors PTCL Lower Risk MDS* Subjects Thyroid n=18 Solid n=18 Urothelial n=18 n=18 (Potential for expansion to n=30) n = 54 1° Endpoint ORR (RECIST v1.1) ORR (IWC) RBC transfusion independence Rationale Preclinical data Pathology series (urotheli
Slide 14: Preclinical ERK Inhibitor – KO-947
Preclinical erk inhibitor – ko-947 ATP active-site inhibitor of ERK Targets well-validated pathway that has led to multiple approved targeted oncology agents Aberrant signaling caused by activating mutations (KRAS, NRAS, BRAF) associated with numerous tumor types BRAF and MEK inhibitors have demonst
Slide 15: KO-947: Strong Activity in BRAF and KRAS Mutant Tumor Models
KO-947: STRONG ACTIVITY IN BRAF and KRAS MUTANT tumor MODELS KO-947 induced tumor regression in BRAF and KRAS mutated tumor models KO-947 compares favorably to clinical-stage reference compound, GDC-0994
Slide 16: KO-947: Strong Activity with Intermittent Dosing Schedule
KO-947: strong activity with intermittent dosing schedule KO-947 displayed comparable anti-tumor activity with intermittent dosing schedule Intravenous administration has potential to improve exposure and tolerability
Slide 17: KO-947: Rationale for Further Study
KO-947: RATIONALE FOR FURTHER STUDY IND-enabling studies ongoing Translational research evaluating potential lead indications IV route of administration selected for initial clinical study Opportunity to advance oral program to broaden indication set Development Plans Anticipated Milestones U.S. Com
Slide 18: Menin-MLL Inhibitor Program
Menin-mll inhibitor program Chromosomal translocations of the MLL gene play a causative role in the onset, development and progression of a subset of acute leukemias Potential first-in-class program targeting the menin-MLL interaction for treatment of MLL-rearranged and MLL-PTD AML and ALL 3,200 pat
Slide 19: Diverse pipeline with potential for near-term value-creating milestones
Diverse pipeline with potential for near-term value-creating milestones PROGRAM EVENT ANTICIPATED TIMING Tipifarnib Phase 2 clinical trial in HRAS mutant solid tumors Ongoing Tipifarnib Phase 2 clinical trial in PTCL Ongoing Tipifarnib Phase 2 IST in HRAS mutant urothelial cancer Ongoing Tipifarnib
Slide 20: Experienced Management Team
Experienced management team Chief Executive Officer Troy Wilson, Ph.D., J.D. Chief Scientific Officer Yi Liu, Ph.D. SVP, Chemistry and Pharm. Sciences Pingda Ren, Ph.D. Chief Medical Officer Antonio Gualberto, M.D., Ph.D. Chief Financial Officer Heidi Henson, CPA SVP and General Counsel Annette Nort
Slide 21: Board and Advisors
Board and advisors Former President and CEO, Receptos, Inc. Faheem Hasnain SVP Finance and CFO, AnaptysBio, Inc. Robert Hoffman CEO and President, Kura Oncology, Inc. Troy Wilson, Ph.D., J.D. Professor and Chairman, Dept. Cellular & Molecular Pharmacology, UCSF Kevan Shokat, Ph.D. Director Emeritus
Slide 22: Corporate Overview
Corporate Overview Develop a diverse pipeline of targeted therapeutics for solid tumors and blood cancers Utilize precision medicine approaches to identify patients most likely to benefit from treatments Fast-to-market strategy; broaden indication set after clinical POC Development Strategy Experien
Slide 23: Slide 23
Kura Oncology — Investor Presentation (February 2016) on 6ix